Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Methods and compositions for treating HIV-associated diarrhea

A correlation and diarrhea technology, applied in drug combinations, active ingredients of hydroxyl compounds, pharmaceutical formulations, etc., can solve problems such as the possibility of addiction and unacceptable side effects

Inactive Publication Date: 2018-01-19
纳珀制药公司
View PDF9 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Currently prescribed treatments are only partially effective or are subject to unacceptable side effects (e.g. constipation) and potential for addiction

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods and compositions for treating HIV-associated diarrhea
  • Methods and compositions for treating HIV-associated diarrhea
  • Methods and compositions for treating HIV-associated diarrhea

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0078] Examples of the preparation and use of Crofelemer are described in U.S. Patent 7,556,831, U.S. Patent Publication 20070254050, and U.S. Patent Publication 20080031984, all of which are incorporated herein by reference in their entirety.

[0079] One embodiment includes a pharmaceutical composition comprising crofelemer and a pharmaceutically acceptable carrier.

[0080] The pharmaceutical composition described herein may also include excipients, such as one or more of diluents, binders, lubricants, disintegrants, coloring agents, flavoring agents, or sweetening agents. The composition can be formulated into selected coated and uncoated tablets, hard and soft gelatin capsules, sugar-coated pills, lozenges, dry paste tablets, small pills and powders in sealed packages. For example, the composition can be formulated into preparations for topical use, such as ointments, hair creams, creams, gels, and lotions.

[0081] In certain embodiments, these pharmaceutical compositions are ...

Embodiment 1

[0148] Example 1: Pulmonary effects of oral administration of Crofelemer in rats

[0149] Crofelemer was administered to three treatment groups of 8 male rats at dose levels of 60, 200 and 600 mg / kg, respectively. Another group of 8 male rats were used as control animals, and vehicle (purified water) was administered. Crofelemer and vehicle were administered at a dose volume of 10 mL / kg. Another group of 8 male rats received the positive control baclofen at a dose level of 100 mg / kg and a dose volume of 15 mL / kg. Crofelemer, positive control substance and vehicle were administered to all groups by oral gavage.

[0150] For all animals, mortality, morbidity, injury, and access to food and water were observed at least twice a day. Clinical observations were performed before administration, approximately 1 hour after administration, and after completion of the lung monitoring period (approximately 4 hours after administration). Measure and record body weight before administration ...

Embodiment 2

[0152] Example 2: 13-week oral toxicity study of Crofelemer administered to mice

[0153] Crofelemer was administered to three groups of 15 male and 15 female mice at dose levels of 40, 400 and 1200 mg / kg / day, respectively. Another group of 15 animals / sex served as a control and received vehicle (purified water). Vehicle or Crofelemer was administered to all groups at a dose volume of 10 mL / kg. In addition, 8 or 39 animals / sex / group of the four groups were used as TK animals, and the doses of 0, 40, 400, or 1200 mg / kg / day were used in the same way as the main research group. The dose level receives the reference substance or Crofelemer. Due to death, Crofelemer was administered to 1200 mg / kg / day main study animals and TK animals for up to 55 or 56 days.

[0154] For all animals, two / day observations were performed on morbidity, mortality, injury, and availability of food and water. Perform detailed clinical observation of clinical signs on all major research animals every week....

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
Login to View More

Abstract

The invention relates to methods and compositions for treating HIV-associated diarrhea. The invention discloses methods for treating diarrhea by administering to a patient in need thereof, an inhibitor of chloride-ion transport in an amount sufficient to treat diarrhea. Treatment of diarrhea includes the treatment of the diarrhea as well as the pain, abdominal discomfort and other symptoms associated with diarrhea. In one embodiment, the inhibitor of chloride-ion transport is crofelemer.

Description

[0001] This application is a divisional application of an invention patent application whose application number is 201180063739.1, the filing date is October 31, 2011, and the invention title is "method and composition for treating HIV-related diarrhea". [0002] Related application [0003] This application requires U.S. Provisional Application No. 61 / 408,622 filed on October 31, 2010, U.S. Provisional Application No. 61 / 409,335 filed on November 2, 2010, and U.S. Provisional Application No. 61 filed on November 22, 2010 / 416,249 and U.S. Provisional Application No. 61 / 434,379 filed on January 19, 2011. The entire contents of each of these applications are incorporated herein by reference. Technical field [0004] The present invention relates to a method and composition for preventing, reducing and / or treating diarrhea, especially HIV-related diarrhea and high-efficiency antiretroviral therapy (HAART)-related diarrhea. Background technique [0005] Despite the widespread use of an...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/353A61P1/12A61P31/18
CPCA61K31/05A61K31/353A61P1/00A61P1/12A61P25/04A61P31/18
Inventor W.福布斯E.博尔泰S.金P.查图维迪
Owner 纳珀制药公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com